NCT02537418 2025-08-19
Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
Canadian Cancer Trials Group
Phase 1 Active not recruiting
Canadian Cancer Trials Group
Canadian Cancer Trials Group